GSK-3 dependent phosphoepitopes recognized by PHF-1 and AT-8 antibodies are present in different tau isoforms

Neurobiology of Aging

Volumn 24, Issue 8, 2003, Pages 1087-1094

  Hernández, Félix ^a   Lucas, José J ^a   Cuadros, Raquel ^a   Avila, Jesús ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Alzheimer's disease; GSK 3; Tau

Indexed keywords

ANTIBODY; AT 8 ANTIBODY; EPITOPE; GLYCOGEN SYNTHASE KINASE 3; ISOPROTEIN; LITHIUM; MONOCLONAL ANTIBODY; PHF 1; PHF 1 ANTIBODY; PHF-1; PROTEIN ANTIBODY; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; ANTIGEN RECOGNITION; BRAIN; BRAIN LEVEL; CELL COMPARTMENTALIZATION; CELLULAR DISTRIBUTION; CHEMISTRY; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFECT; ENZYMOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOLOGY; METABOLISM; MOLECULAR GENETICS; NERVE CELL; NEUROPATHOLOGY; NONHUMAN; PHOSPHORYLATION; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; TUMOR CELL LINE;

EID: 0345276564     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2003.04.002     Document Type: Conference Paper

References (45)

1. Alzheimer A. Über eigernartige krankhertsfülle des späteren alters. Z. Ges. Neurol. Psychiat. 4:1911;356-385.
2. Anderton B.H. Alzheimer's disease: clues from flies and worms. Curr. Biol. 9:1999;R106-R109.
3. Arrasate M., Perez M., Avila J. Tau dephosphorylation at tau-1 site correlates with its association to cell membrane. Neurochem. Res. 25:2000;43-50.
4. Arriagada P.V., Growdon J.H., Hedley-Whyte E.T., Hyman B.T. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology. 42:1992;631-639.
5. Barth A.I., Nathke I.S., Nelson W.J. Cadherins, catenins and APC protein: interplay between cytoskeletal complexes and signaling pathways. Curr. Opin. Cell Biol. 9:1997;683-690.
6. Biernat J., Mandelkow E.M., Schroter C., Lichtenberg-Kraag B., Steiner B., Berling B.et al. The switch of tau protein to an Alzheimer-like state includes the phosphorylation of two serine-proline motifs upstream of the microtubule binding region. EMBO J. 11:1992;1593-1597.
7. Binder L.I., Frankfurter A., Rebhun L.I. The distribution of tau in the mammalian central nervous system. J. Cell Biol. 101:1985;1371-1378.
8. Bondareff W., Mountjoy C.Q., Roth M., Hauser D.L. Neurofibrillary degeneration and neuronal loss in Alzheimer's disease. Neurobiol. Aging. 10:1989;709-715.
9. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82:1991;239-259.
10. Buee-Scherrer V., Condamines O., Mourton-Gilles C., Jakes R., Goedert M., Pau B.et al. AD2, a phosphorylation-dependent monoclonal antibody directed against tau proteins found in Alzheimer's disease. Brain Res. Mol. Brain Res. 39:1996;79-88.
11. de Ancos J.G., Avila J. Differential distribution in white and gray matter of tau phosphoisoforms containing four tubulin-binding motifs. Biochem. J. 296:1993;351-354.
12. Drubin D.G., Kirschner M.W. Tau protein function in living cells. J. Cell Biol. 103:1986;2739-2746.
13. Frame S., Cohen P. GSK3 takes centre stage more than 20 years after its discovery. Biochem. J. 359:2001;1-16.
14. Garcia de Ancos J., Correas I., Avila J. Differences in microtubule binding and self-association abilities of bovine brain tau isoforms. J. Biol. Chem. 268:1993;7976-7982.
15. Goedert M. Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies. Philos. Trans. R. Soc. Lond. B: Biol. Sci. 354:1999;1101-1118.
16. Goedert M., Jakes R., Crowther R.A., Cohen P., Vanmechelen E., Vandermeeren M.et al. Epitope mapping of monoclonal antibodies to the paired helical filaments of Alzheimer's disease: identification of phosphorylation sites in tau protein. Biochem. J. 301:1994;871-877.
17. Goedert M., Spillantini M.G., Jakes R., Rutherford D., Crowther R.A. Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron. 3:1989;519-526.
18. Goedert M., Spillantini M.G., Potier M.C., Ulrich J., Crowther R.A. Cloning and sequencing of the cDNA encoding an isoform of microtubule- associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain. EMBO J. 8:1989;393-399.
19. Greenberg S.G., Davies P. A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis. Proc. Natl. Acad. Sci. U.S.A. 87:1990;5827-5831.
20. Greenberg S.G., Davies P., Schein J.D., Binder L.I. Hydrofluoric acid-treated tau PHF proteins display the same biochemical properties as normal tau. J. Biol. Chem. 267:1992;564-569.
21. Grundke-Iqbal I., Iqbal K., Tung Y.C., Quinlan M., Wisniewski H.M., Binder L.I. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc. Natl. Acad. Sci. U.S.A. 83:1986;4913-4917.
22. Heutink P. Untangling tau-related dementia. Hum. Mol. Genet. 9:2000;979-986.
23. Hong M., Chen D.C., Klein P.S., Lee V.M. Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase 3. J. Biol. Chem. 272:1997;25326-25332.
24. Kosik K.S. Alzheimer's disease: a cell biological perspective. Science. 256:1992;780-783.
25. Lee V.M., Goedert M., Trojanowski J.Q. Neurodegenerative tauopathies. Annu. Rev. Neurosci. 24:2001;1121-1159.
26. Lindwall G., Cole R.D. Phosphorylation affects the ability of tau protein to promote microtubule assembly. J. Biol. Chem. 259:1984;5301-5305.
27. Liu C., Li Y., Semenov M., Han C., Baeg G.H., Tan Y.et al. Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell. 108:2002;837-847.
28. Lovestone S., Hartley C.L., Pearce J., Anderton B.H. Phosphorylation of tau by glycogen synthase kinase-3 beta in intact mammalian cells: the effects on the organization and stability of microtubules. Neuroscience. 73:1996;1145-1157.
29. Lovestone S., Reynolds C.H., Latimer D., Davis D.R., Anderton B.H., Gallo J.M.et al. Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells. Curr. Biol. 4:1994;1077-1086.
30. Lucas J.J., Hernandez F., Gomez-Ramos P., Moran M.A., Hen R., Avila J. Decreased nuclear beta-catenin tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J. 20:2001;27-39.
31. Maas T., Eidenmuller J., Brandt R. Interaction of tau with the neural membrane cortex is regulated by phosphorylation at sites that are modified in paired helical filaments. J. Biol. Chem. 275:2000;15733-15740.
32. Mandell J.W., Banker G.A. A spatial gradient of tau protein phosphorylation in nascent axons. J. Neurosci. 16:1996;5727-5740.
33. Mercken M., Vandermeeren M., Lubke U., Six J., Boons J., Van de Voorde A.et al. Monoclonal antibodies with selective specificity for Alzheimer Tau are directed against phosphatase-sensitive epitopes. Acta Neuropathol. 84:1992;265-272.
34. Morishima-Kawashima M., Hasegawa M., Takio K., Suzuki M., Yoshida H., Titani K.et al. Proline-directed and non-proline-directed phosphorylation of PHF-tau. J. Biol. Chem. 270:1995;823-829.
35. Mukai F., Ishiguro K., Sano Y., Fujita S.C. Alternative splicing isoform of tau protein kinase I/glycogen synthase kinase 3beta. J. Neurochem. 81:2002;1073-1083.
36. Munoz-Montano J.R., Moreno F.J., Avila J., Diaz-Nido J. Lithium inhibits Alzheimer's disease-like tau protein phosphorylation in neurons. FEBS Lett. 411:1997;183-188.
37. Novak M., Jakes R., Edwards P.C., Milstein C., Wischik C.M. Difference between the tau protein of Alzheimer paired helical filament core and normal tau revealed by epitope analysis of monoclonal antibodies 423 and 7.51. Proc. Natl. Acad. Sci. U.S.A. 88:1991;5837-5841.
38. Otvos L., Feiner L., Lang E., Szendrei G.I., Goedert M., Lee V.M. Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 AMD 404. J. Neurosci. Res. 39:1994;669-673.
39. Papasozomenos S.C., Binder L.I. Phosphorylation determines two distinct species of Tau in the central nervous system. Cell Motil. Cytoskeleton. 8:1987;210-226.
40. Pei J.J., Braak E., Braak H., Grundke-Iqbal I., Iqbal K., Winblad B.et al. Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes. J. Neuropathol. Exp. Neurol. 58:1999;1010-1019.
41. Sadqi M., Hernandez F., Pan U., Perez M., Schaeberle M.D., Avila J.et al. Alpha-helix structure in Alzheimer's disease aggregates of tau-protein. Biochemistry. 41:2002;7150-7155.
42. Sergeant N., David J.P., Lefranc D., Vermersch P., Wattez A., Delacourte A. Different distribution of phosphorylated tau protein isoforms in Alzheimer's and Pick's diseases. FEBS Lett. 412:1997;578-582.
43. Seubert P., Mawal-Dewan M., Barbour R., Jakes R., Goedert M., Johnson G.V. et al. Detection of phosphorylated Ser262 in fetal tau, adult tau, and paired helical filament tau. J. Biol. Chem. 270:1995;18917-18922.
44. Shiurba R.A., Ishiguro K., Takahashi M., Sato K., Spooner E.T., Mercken M. et al. Immunocytochemistry of tau phosphoserine 413 and tau protein kinase I in Alzheimer pathology. Brain Res. 737:1996;119-132.
45. Woodgett J.R. Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J. 9:1990;2431-2438.